ANI Pharmaceuticals, Inc. (ANIP)

Price$76.71

Value ScoreC

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-15.94%

Price vs S&P 500 (4W)-7.31%

VGM Score63.81

Market Capitalization$1.79B

P/E Ratio (Annual)22.90x

All Metrics

P/CF (Annual)9.68x

Book Value / Share (Quarterly)$24.57

P/TBV (Annual)28.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)40.81%

Cash Flow / Share (Quarterly)$8.35

Payout Ratio (TTM)2.28%

Price vs S&P 500 (YTD)-11.48%

Gross Margin (TTM)60.83%

Net Profit Margin (TTM)9.98%

EPS (TTM)$4.29

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$4.29

Revenue Growth (5Y)33.48%

EPS (Annual)$3.69

Dividend / Share (Annual)$0.05

ROI (Annual)6.77%

Gross Margin (Annual)61.36%

Net Profit Margin (5Y Avg)-5.03%

Cash / Share (Quarterly)$14.25

P/E Basic Excl Extra (TTM)19.47x

Revenue Growth QoQ (YoY)20.46%

P/E Normalized (Annual)22.90x

ROA (Last FY)5.44%

Revenue Growth TTM (YoY)37.03%

EBITD / Share (TTM)$10.02

ROE (5Y Avg)-2.35%

Operating Margin (TTM)13.40%

Cash Flow / Share (Annual)$7.62

P/B Ratio3.19x

P/B Ratio (Quarterly)3.11x

Net Income / Employee (Annual)$80,800

EV / Revenue (TTM)2.27x

Net Interest Coverage (TTM)6.56x

ROA (TTM)6.57%

EPS Growth QoQ (YoY)74.98%

EV / EBITDA (TTM)9.83x

EPS Incl Extra (Annual)$3.69

Current Ratio (Annual)2.71x

Quick Ratio (Quarterly)2.43x

3-Month Avg Trading Volume0.37M

52-Week Price Return34.76%

EV / Free Cash Flow (Annual)12.23x

P/E Incl Extra (TTM)19.47x

Revenue / Employee (TTM)$952,300

Tangible BV / Share (Quarterly)$4.16

P/S Ratio (Annual)2.03x

Asset Turnover (Annual)0.61x

52-Week High$99.50

Operating Margin (5Y Avg)-1.69%

EPS Excl Extra (Annual)$3.69

CapEx CAGR (5Y)17.64%

Tangible BV CAGR (5Y)13.56%

26-Week Price Return-0.01%

Quick Ratio (Annual)2.07x

13-Week Price Return1.76%

Total Debt / Equity (Annual)1.14x

Current Ratio (Quarterly)3.12x

Enterprise Value$2.10B

Revenue / Share Growth (5Y)19.09%

Asset Turnover (TTM)0.66x

Book Value / Share Growth (5Y)8.77%

Revenue / Employee (Annual)$910,700

Inventory Turnover (Annual)2.44x

Pretax Margin (Annual)10.84%

Cash / Share (Annual)$13.10

3-Month Return Std Dev31.95%

Gross Margin (5Y Avg)58.58%

Net Income / Employee (TTM)$95,000

EBITDA CAGR (5Y)47.92%

EBITDA Interim CAGR (5Y)33.89%

ROE (Last FY)14.49%

Net Interest Coverage (Annual)6.56x

EPS Basic Excl Extra (Annual)$3.69

P/FCF (TTM)9.38x

Receivables Turnover (TTM)3.88x

EV / Free Cash Flow (TTM)10.97x

Total Debt / Equity (Quarterly)1.09x

EPS Incl Extra (TTM)$4.29

Receivables Turnover (Annual)3.51x

ROI (TTM)8.11%

P/S Ratio (TTM)1.94x

Pretax Margin (5Y Avg)-6.90%

Revenue / Share (Annual)$41.61

Tangible BV / Share (Annual)$2.72

Forward P/E7.91x

Free OCF CAGR (5Y)79.76%

Price vs S&P 500 (52W)6.55%

P/E Ratio (TTM)19.47x

EPS Growth TTM (YoY)237.36%

Year-to-Date Return-0.54%

5-Day Price Return-5.09%

EPS Normalized (Annual)$3.69

ROA (5Y Avg)-1.15%

Net Profit Margin (Annual)8.87%

Month-to-Date Return-1.18%

Cash Flow / Share (TTM)$4.03

EBITD / Share (Annual)$9.54

Operating Margin (Annual)12.58%

LT Debt / Equity (Annual)1.11x

P/CF (TTM)8.60x

ROI (5Y Avg)-1.34%

P/E Excl Extra (TTM)19.47x

LT Debt / Equity (Quarterly)1.06x

EPS Basic Excl Extra (TTM)$4.29

P/TBV (Quarterly)18.40x

Payout Ratio (Annual)1.48%

P/B Ratio (Annual)3.28x

Dividend / Share (TTM)$0.03

Inventory Turnover (TTM)2.58x

Pretax Margin (TTM)12.56%

Book Value / Share (Annual)$24.03

Price vs S&P 500 (13W)-7.98%

Dividend Yield (TTM)0.04%

Beta0.45x

P/FCF (Annual)10.47x

Revenue / Share (TTM)$42.88

ROE (TTM)17.80%

52-Week Low$57.33

vGradeC

gGradeA

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 262.05est. 1.33

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.21

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ANIPANI Pharmaceuticals, Inc.	C	A	C	$76.71
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

ANI Pharmaceuticals manufactures and markets generic prescription medications, specializing in narcotics, hormones, steroids, and complex formulations including extended-release and combination products. The company operates two business segments—Rare Diseases and Brands, Generics, and Others—with primary operations in the United States and a smaller Canadian presence.